Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 1

1(20.0%)

Phase 4

1(20.0%)

Early Phase 1

1(20.0%)

5Total

N/A(2)

Phase 1(1)

Phase 4(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05212610Phase 4Completed

Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction

Role: collaborator

NCT06464367Early Phase 1Recruiting

Mechanistic Studies of Psilocybin in Headache Disorders

Role: collaborator

NCT04218539Phase 1Completed

Repeat Dosing of Psilocybin in Migraine Headache

Role: collaborator

NCT04277715Not ApplicableCompleted

Parent Training for Youth With Chronic Symptoms

Role: collaborator

NCT03174808Not ApplicableTerminated

Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL)

Role: collaborator

All 5 trials loaded